Leonard S Kaczmarek

US Patent:

6861405, Mar 1, 2005

Filed:

Jun 11, 2002

Appl. No.:

10/167528

Inventors:

Gary Desir - Woodbridge CT, US
Jianchao Xu - Bethany CT, US
Pandelakis A. Koni - Martinez GA, US
Leonard Kaczmarek - Guilford CT, US
Richard A. Flavell - Guilford CT, US

Assignee:

Yale University - New Haven CT

International Classification:

A61K038/17

US Classification:

514 12

Abstract:

The present invention relates to weight control, control of body fat and food intake, and provides useful methods for treating, inter alia, obesity, diabetes and insulin insensitivity, and conditions, diseases, and disorders relating thereto. The invention also relates to methods of identifying useful compounds relating to weight loss, food intake, diabetes, and obesity, among other things, based on the discovery that inhibiting Kv1. 3 activity mediates decreased food intake, weight loss, decreased body fat, increase glucose uptake, and increased insulin sensitivity, among other things.

US Patent:

20030078403, Apr 24, 2003

Filed:

Jun 25, 2002

Appl. No.:

10/178791

Inventors:

Leonard Kaczmarek - Guilford CT, US
Michael Tang - New Haven CT, US
Manjunath Nimmakayalu - New Haven CT, US

International Classification:

C07H021/04
C12Q001/68

US Classification:

536/023200, 435/006000

Abstract:

Polymorphisms are identified in a human gene which encodes a voltage-gated ion channel. The gene maps to the same portion of human chromosome 13q22 to which genes for schizophrenia susceptibility, Bipolar Disorder, and Panic Disorder Syndrome have been mapped. The polymorphisms are used to follow inheritance of the susceptibilities within families. They are also used to identify affected probands. A complete mRNA sequence and genomic structure provide insights into function and relationship to other ion channels.